When Associate Professor Sudarshini (Darshi) Ramanathan began her medical career, autoimmune neurology was still an emerging field.
At the time, much of the focus in neurology was on neurodegenerative diseases such as Parkinson’s and Alzheimer’s. But researchers were beginning to understand that some patients with unexplained neurological symptoms, including those initially thought to have been due to multiple sclerosis (MS) or an infectious encephalitis, were not responding to standard treatment with MS therapies or antimicrobial agents, and were actually experiencing autoimmune activity in the central nervous system.
In the last two decades, there has been an increasing awareness of newly recognised antibody-mediated diseases that result in inflammation of the grey (encephalitis) or white (demyelination) matter of the brain, that account for the majority of these previously unknown entities.
For Associate Professor Ramanathan, a neurologist and clinician scientist at the University of Sydney, the field was compelling because of what was at stake.
These disorders can affect previously healthy children as young as six months of age to adults in their 90s, and cause devastating outcomes, including blindness, paralysis, seizures, or death. But they also offer the possibility of recovery.
“The really big drawcard for me was that if you can diagnose these disorders accurately and early, and if you can figure out the right immune treatment, you can reverse this disability, and these patients have a chance to live a normal fulfilling life,” she says. “If you do it quickly and you do it right, you avoid misdiagnosis or missed diagnoses, and with the appropriate treatment, you can give people who risk losing everything, an excellent quality of life. There is a lot at stake here.”
That combination of scientific discovery and the potential to make an immediate difference to patients ultimately led Associate Professor Ramanathan to subspecialise in neuroimmunology.
Today, she is helping lead a rapidly evolving field that is reshaping how some of the most complex and recently identified neurological diseases are managed. She has and continues to lead consensus diagnostic and therapeutic guidelines in the field.
Her work has now received a major boost through an $8 million Snow Fellowship, providing long-term support for research into autoimmune neurological disorders and the development of more precise diagnostics and treatments.
The investment will allow her team to investigate the pathogenesis of what drives immune dysfunction in the central nervous system, develop more accurate diagnostic tools which can be translated into clinical practice, and identify targeted treatments and develop therapeutic guidelines that could prevent or reverse neurological disability.
Tom Snow, Chair of Snow Medical Research Foundation, says Darshi Ramanathan’s combination of research expertise and clinical experience was central to her selection as a Snow Fellow.
“What stands out about Darshi is that she is both an outstanding clinician and an outstanding scientist. She sees first-hand the impact these conditions have on patients and their families, and she has the scientific curiosity and determination to tackle the underlying causes. That's exactly the kind of researcher we look to support through Snow Medical. We are proud to back her as she works towards better diagnosis, treatments and outcomes for people affected by these devastating disorders."
Targeted treatments
As researchers have learned more about the mechanisms behind these diseases, treatment targets have also become increasingly precise.
Traditionally, patients were often treated with high-dose steroids and other highly potent agents that suppressed multiple facets of the immune system. While effective in reducing autoimmunity, broad immune suppression can also leave patients vulnerable to significant complications including life-threatening infections.
Now, researchers are increasingly able to identify the precise immune mechanisms driving some of those diseases and target those instead.
“In neuroimmunology, we’re probably currently where cancer was 15 years ago,” she says. “There is such a long way to go still, but the work is accelerating. We are making exciting and rapid progress.”
For Snow Medical, the relative newness of the field and its potential to change outcomes for patients make it an important area for investment.
“Antibody-mediated autoimmune neurological diseases are a relatively new field of medicine, which makes Darshi’s research so exciting. There is enormous potential for new discoveries which might improve diagnosis and treatment and could have a profound impact on patients and their families."
We give researchers the confidence and time frame to think big, take on challenging questions and build programs of work that can make a lasting difference.
Tom Snow
Chair of Snow Medical Research Foundation
Time to pursue the difficult questions
It is that next phase of discovery that the Snow Fellowship is designed to support. Associate Professor Ramanathan was one of three researchers selected as Snow Fellows for 2026, as part of Snow Medical’s $300 million investment in Australian medical research since its inception in 2019.
The Fellowship provides $8 million over eight years, giving researchers sustained support to pursue ambitious work that can be difficult to achieve within traditional short-term grant cycles.
Snow says the length and scale of that support are deliberate.
“We give researchers the confidence and time frame to think big, take on challenging questions and build programs of work that can make a lasting difference” he says.
For Associate Professor Ramanathan, that stability is transformative. “It is a completely unprecedented opportunity when you lead a basic science and clinical research program,” she says. “To have the security to lead a translational research program for such an extended period of time removes a lot of the constraints that we normally face as researchers - which is basically a lack of a safety net to tackle difficult and high risk, but also high gain questions.”
Those constraints are familiar across the research sector. Researchers can spend significant amounts of time applying for three or four-year grants, while also trying to retain talented team members whose positions depend on their lead investigators securing the next round of funding. Long-term philanthropic support allows researchers to think differently.
“What it gives me is the capacity to do is to now focus on the really slow burn, long, hard, interesting projects, which I haven’t yet had the bandwidth or the stability or the funding to do,” Associate Professor Ramanathan says. “We don’t have to do quick wins, we can now focus on big wins that will change understanding and practice.”
Philanthropy as research investment
For Associate Professor Ramanathan, the Fellowship has also changed the way she thinks about philanthropy’s role in Australian medical research. She built her research career on competitive Category 1 government funding, with four consecutive NHMRC fellowships spanning 19 years. She is grateful to NHMRC for providing her with that protected research time and resourcing, to which she credits her ability to develop her career as a clinician-scientist. Behind that journey is the unwavering support of her husband, her greatest source of encouragement and strength throughout her career. “He is always there, supporting and encouraging me, believing in me when I didn’t believe in myself, and being a genuine life partner, while also working full time in a senior role himself and sharing the upbringing of our lovely twins. I would not have been able to achieve this career without him.”
But she has seen highly competitive researchers miss out as success rates for major grants continue to plummet. “While you of course have to be good to be lucky, the way things are going, you still have to be very, very lucky indeed.” The consequence, she says, is not simply that individual projects go unfunded. Australia risks losing talented researchers who leave science and research – a critical pipeline for discovery and innovation.
“Philanthropy in Australia is critical to provide an alternate opportunity for funding,” she says. “Clever countries invest in clever people, as the saying goes.”
She has also been struck by the Snow family’s close involvement in the Fellowship program.
“I believe they’ve got a really amazing vision of what could be achieved, and they’re central to executing it. They are building this innovative health and medical research Snow ecosystem in Australia which I believe is unparalleled globally, and it is an absolute privilege to be a small part of it,” she says.
A future of faster diagnosis
Associate Professor Ramanathan’s long-term goal is for these patients who often struggle with misdiagnosis and missed diagnoses to be identified earlier, including outside specialist centres, and receive treatments targeted to the precise mechanisms driving their disease. That combination of basic science research informing diagnosis and treatment will inevitably result in improved outcomes. It is a vision founded in her dual role as both a clinician and a scientist.
“What are the things my patients struggle with? What are the problems my colleagues and I grapple with and still don’t understand? These questions serve as the launch pad for where I would like to focus my team’s research priorities,” she says. “Being able to see the benefits of our research realised in my own patients, but hopefully to see that our work also helps patients beyond those that we’re directly caring for, nationally and internationally, is what puts the fire in my belly.”
Hero image: Stefanie Zingsheim/ University of Sydney
Members of the Translational Neuroimmunology Group, left to right, Ms Isabella Cotter, Dr Fiona Chan, Associate Professor Sudarshini Ramanathan, Dr Magdalena Lerch. Credit: University of Sydney/ Emlyn Crockett
50
automatic
Link